NEW YORK – South Korean cancer firm Deep Bio said this week that it has joined CancerX, a public-private partnership that is part of the White House Cancer Moonshot program and is aimed at innovating new approaches against cancer. Deep Bio provides in vitro diagnostic software powered by deep-learning algorithms as a medical device. According to the firm, the software improves the accuracy and efficiency of cancer diagnosis, allowing healthcare providers to make better treatment decisions.
Landmark Bio said this week that it has signed a deal with the biotech Galapagos to manufacture clinical trial batches of Galapagos' autologous CAR T-cell therapies for hematology and oncology at its Boston-area facilities. The agreement is part of Galapagos' goal of achieving a seven-day manufacturing turnaround time for CAR T-cell therapies through a decentralized model.
Telix Pharmaceuticals said this week that it has signed a deal with Wiik Pharma to distribute Telix's prostate cancer imaging agent, Illuccix (TLX591-CDx). For its part of the deal, the Denmark-based Wiik will be the exclusive commercial distributor of Illuccix in Denmark, Finland, Norway, and Sweden for a period of three years following commercial approval in these respective regions.
The Max Foundation said this week that three patients with hormone receptor-positive, HER2-negative advanced breast cancer in Mozambique have begun receiving targeted therapies, including CDK4/6 inhibitor treatment, through its Max Access Solutions program. The organization is working with partners through the Humanitarian Partnership for Access to Critical Treatment (Humanitarian PACT) for Advanced Breast Cancer to provide access to precision medicine to cancer patients in low-resource countries at no cost. Humanitarian PACT partners — including oncologists in low- and middle-income countries, the ABC Global Alliance, the American Society for Clinical Pathology, Cepheid, and Novartis — have agreed to provide more support and investment to expand Max Access Solutions.
Roche this week announced that its Elecsys Neurofilament Light Chain test for Multiple Sclerosis has received breakthrough device designation from the US Food and Drug Administration. The minimally invasive test is intended as an aid for the detection of disease activity in adults ages 18 to 55 with relapsing-remitting multiple sclerosis or secondary progressive multiple sclerosis, the company said in a statement.
In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared in Precision Medicine Online.